BERLIN & OSLO, Norway--(BUSINESS WIRE)--ProBioGen AG, and Affitech AS, jointly announced today that they have entered into an agreement for a biopharmaceutical cell line to be developed by ProBioGen for high-level production of one of the lead candidates in Affitech’s oncology therapeutic antibody pipeline.
